Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV.
Journal Article (Journal Article)
The difficulty in developing an effective vaccine to contain the HIV/AIDS epidemic coupled with the fact that primary HIV-1 infection typically occurs via mucosal sites has increased emphasis on vaccine approaches that protect at mucosal surfaces. In this study we employed HIV and simian-HIV (SHIV)-derived T helper (Th) and cytotoxic T lymphocyte (CTL) single epitopes incorporated into immuno-stimulating complexes (ISCOM) as a candidate immunogens. Immunized rhesus macaques (Macaca mulatta) were challenged with CCR5-tropic SHIV(SF162p4). On the day of challenge, low levels of virus-neutralizing antibodies (Ab) and CTLs were detected in ISCOM-immunized macaques. Greater than 10(5) viral RNA copies per ml of plasma in 2/5 immunized and 3/4 control macaques were detected within 3 weeks post-challenge. Depletion of CD4+ T cells from gut-associated lymphoid tissues (GALT) was observed by post-challenge day (PCD) 14 in all macaques regardless immunization. Nonetheless, lower viral loads and relatively better preservation of peripheral CD4+ T cells following the SHIV infection was observed in ISCOM-immunized macaques. We predict that if coadministered with additional epitopes and/or more efficacious mucosal delivery system or route, HIV/SIV-derived peptide vaccines may have potential to elicit heterologous protection.
- Pahar, B; Cantu, MA; Zhao, W; Kuroda, MJ; Veazey, RS; Montefiori, DC; Clements, JD; Aye, PP; Lackner, AA; Lovgren-Bengtsson, K; Sestak, K
- November 17, 2006
Volume / Issue
- 24 / 47-48
Start / End Page
- 6839 - 6849
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)